Roth Capital Positive on Stemline Therapeutics (STML) Ahead of ASH Amid SL-701 'Surprise'
Tweet Send to a Friend
Roth Capital affirms Stemline Therapeutics, Inc. (Nasdaq: STML) at Buy with a price target of $32 ahead of ASH and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
